Dual-responsive nanoparticles targeting bone microenvironment for synergistic chemoimmunotherapy of osteosarcoma by remodeling immune microenvironment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immune cells in cancer · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Cancer statistics, 2018
2. Osteosarcoma10.1093/annonc/mdq276 ↗
3. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs10.1016/j.canlet.2020.12.024 ↗
4. New horizons in the treatment of osteosarcoma10.1056/NEJMra2103423 ↗
5. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program10.1002/cncr.24121 ↗
6. Bone microenvironment signals in osteosarcoma development10.1007/s00018-015-1918-y ↗
7. Cancer stem cells in osteosarcoma10.1016/j.canlet.2016.11.019 ↗
8. In vitro demonstration of humoral and cell-bound immunity against common specific transplantation antigen(s) of adenovirus 12-induced mouse and hamster tumors10.1084/jem.125.6.1105 ↗
9. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis10.1016/j.canlet.2018.10.011 ↗
10. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment10.1073/pnas.1720948115 ↗
11. Prodrug-based versatile nanomedicine for enhancing cancer immunotherapy by increasing immunogenic cell death10.1002/smll.202000214 ↗
12. Diselenide-based dual-responsive prodrug as pyroptosis inducer potentiates cancer immunotherapy10.1002/adhm.202202135 ↗
13. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy10.1016/j.jconrel.2022.08.054 ↗
14. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
15. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
16. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy
17. The mevalonate pathway is a druggable target for vaccine adjuvant discovery10.1016/j.cell.2018.08.070 ↗
18. Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery10.1200/JCO.2015.60.7481 ↗
19. Self‐amplified drug delivery with light‐inducible nanocargoes to enhance cancer immunotherapy10.1002/adma.201902960 ↗
20. Versatile prodrug nanoparticles for acid-triggered precise imaging and organelle-specific combination cancer therapy10.1002/adfm.201602963 ↗
21. Photo‐reduction with NIR light of nucleus‐targeting Pt IV nanoparticles for combined tumor‐targeted chemotherapy and photodynamic immunotherapy10.1002/anie.202201486 ↗
22. Serum protein-based nanoparticles for cancer diagnosis and treatment10.1016/j.jconrel.2020.10.030 ↗
23. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment10.1021/jacs.2c02706 ↗
24. Engineered nanomedicines with enhanced tumor penetration10.1016/j.nantod.2019.100800 ↗
25. First-in-human phase I study of ABBV-085, an antibody–drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors10.1158/1078-0432.CCR-20-4513 ↗
26. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis10.1073/pnas.1603316113 ↗
27. bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer10.1002/adhm.201601119 ↗
28. Self-assembled peptide and protein nanostructures for anti-cancer therapy: targeted delivery, stimuli-responsive devices and immunotherapy10.1016/j.nantod.2021.101119 ↗
29. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid10.1182/blood-2006-09-044321 ↗
30. Host cell mimic polymersomes for rapid detection of highly pathogenic influenza virus via a viral fusion and cell entry mechanism10.1002/adfm.201800960 ↗
31. Photosynthesis-inspired H2 generation using a chlorophyll-loaded liposomal nanoplatform to detect and scavenge excess ROS10.1038/s41467-020-14413-x ↗
32. Nano-ultrasonic contrast agent for chemoimmunotherapy of breast cancer by immune metabolism reprogramming and tumor autophagy10.1021/acsnano.2c00462 ↗
33. PLGA-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
34. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release10.1021/acs.chemrev.5b00346 ↗
35. Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt pathways10.1186/s13046-019-1109-z ↗
36. Zoledronic acid reverses the epithelial–mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB10.1158/1535-7163.MCT-12-0304 ↗
37. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
38. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/anie.201804882 ↗
39. Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases10.1016/j.autrev.2013.10.010 ↗
40. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells10.1016/j.ccell.2021.12.009 ↗
41. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response10.1038/s41467-017-00729-8 ↗
42. Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis10.1038/s41467-022-30543-w ↗
43. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
44. Neoadjuvant checkpoint blockade for cancer immunotherapy10.1126/science.aax0182 ↗
45. Multifunctional albumin–MnO2 nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response10.1021/nn405773r ↗
46. Tumor-associated macrophages: an accomplice in solid tumor progression10.1186/s12929-019-0568-z ↗
47. Tumor-associated macrophages in tumor immunity10.3389/fimmu.2020.583084 ↗
48. Tumor microenvironment-modulated multiple nanotherapeutic system for potent cancer immunotherapy and metastasis inhibition
49. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses10.1126/scitranslmed.aax6337 ↗
50. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer10.1038/s41392-021-00670-9 ↗
51. Regulatory T cells in cancer immunotherapy10.1038/cr.2016.151 ↗
52. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
53. The roles of CD8+ T cell subsets in antitumor immunity10.1016/j.tcb.2020.06.003 ↗
54. Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFN gamma/Stat1 signals10.1182/blood-2006-11-058271 ↗
55. The relationship between the expression of Ki-67 and the prognosis of osteosarcoma10.1186/s12885-021-07880-y ↗
56. Prognostic and clinicopathological value of Ki-67 in melanoma: a meta-analysis
57. WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion10.1038/s41467-020-18951-2 ↗